Abstract
Background:
Prenatal ethylene oxide exposure may have adverse effects on fetal development. We examined the relationships between ethylene oxide hemoglobin (Hb) adduct levels and offspring’s size at birth in a prospective European mother–child study.
Methods:
This study included 1106 singletons from the NewGeneris project (2006–2010) with ethylene oxide Hb adducts measured in cord blood. We examined the relationships between adduct levels and offspring’s size at birth among all infants and separately among infants of nonsmokers, using linear regression models for birth weight and birth head circumference and logarithmic binomial regression models for small for gestational age. We examined potential interactions between CYP2E1 single nucleotide polymorphisms in cord blood and the effects of ethylene oxide Hb adduct levels on offspring birth size.
Results:
Higher quartiles of adduct levels as a measure of exposure were associated with decreasing birth weight and head circumference in the overall population. Compared to infants in the lowest quartile, those in the highest quartile exhibited lower birth weight (−70.73 g, 95% confidence interval = −141.16, −0.30) and reduced head circumference (−0.30 cm, 95% confidence interval = −0.58, −0.02). We observed similar, albeit less pronounced, patterns among infants of nonsmokers. There was no evidence of an association between ethylene oxide Hb adducts and risk of small for gestational age, nor consistent evidence of an interaction with CYP2E1 polymorphisms on the association between EO Hb adduct levels and offspring’s size at birth.
Conclusion:
Results suggest that higher ethylene oxide Hb adduct levels in cord blood are associated with a reduction in offspring birth size.
Prenatal ethylene oxide exposure may have adverse effects on fetal development. We examined the relationships between ethylene oxide hemoglobin (Hb) adduct levels and offspring’s size at birth in a prospective European mother–child study.
Methods:
This study included 1106 singletons from the NewGeneris project (2006–2010) with ethylene oxide Hb adducts measured in cord blood. We examined the relationships between adduct levels and offspring’s size at birth among all infants and separately among infants of nonsmokers, using linear regression models for birth weight and birth head circumference and logarithmic binomial regression models for small for gestational age. We examined potential interactions between CYP2E1 single nucleotide polymorphisms in cord blood and the effects of ethylene oxide Hb adduct levels on offspring birth size.
Results:
Higher quartiles of adduct levels as a measure of exposure were associated with decreasing birth weight and head circumference in the overall population. Compared to infants in the lowest quartile, those in the highest quartile exhibited lower birth weight (−70.73 g, 95% confidence interval = −141.16, −0.30) and reduced head circumference (−0.30 cm, 95% confidence interval = −0.58, −0.02). We observed similar, albeit less pronounced, patterns among infants of nonsmokers. There was no evidence of an association between ethylene oxide Hb adducts and risk of small for gestational age, nor consistent evidence of an interaction with CYP2E1 polymorphisms on the association between EO Hb adduct levels and offspring’s size at birth.
Conclusion:
Results suggest that higher ethylene oxide Hb adduct levels in cord blood are associated with a reduction in offspring birth size.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Epidemiology |
| Vol/bind | 35 |
| Udgave nummer | 5 |
| Sider (fra-til) | 710-720 |
| Antal sider | 11 |
| ISSN | 1044-3983 |
| DOI | |
| Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:The NewGeneris (Newborns and Genotoxic Exposure Risks) study was funded by the European Union (EU Contract FOOD-CT-2005-016320). The study was also supported by grants obtained locally, including the Swedish Cancer and Allergy Foundation and the Swedish Research Council Formas, the National Institute for Health Research, UK (programme grant RP-PG-0407-10044), the Norwegian Ministry of Health, the Norwegian Ministry of Education and Research, the Norwegian Research Council/FUGE (grant 151918/S10), the EU funded HiWATE (contract Food-CT-2006-036224), the US National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (contract NO-ES75558), and the US NIH/National Institute of Neurological Disorders and Stroke (grant 1 UO1 NS 047537-01). M.P. holds a Juan de la Cierva postdoctoral fellowship awarded from the Spanish Ministry of Science and Innovation (JCI-2011-09479) while preparing the pooled data and conducting the initial statistical analyses for the current study and has received funding from the European Research Council (ERC) under the European Union\u2019s Horizon 2020 research and innovation programme (grant agreement No 758151) for CHIPS. B.N.H. has received funding from the Instituto de Salud Carlos III (ISCIII) and the European Union NextGenerationEU/PRTR (Grant IHMC22/00017).
Funding Information:
The NewGeneris (Newborns and Genotoxic Exposure Risks) study was funded by the European Union (EU Contract FOOD-CT-2005-016320). The study was also supported by grants obtained locally, including the Swedish Cancer and Allergy Foundation and the Swedish Research Council Formas, the National Institute for Health Research, UK (programme grant RP-PG-0407-10044), the Norwegian Ministry of Health, the Norwegian Ministry of Education and Research, the Norwegian Research Council/FUGE (grant 151918/S10), the EU funded HiWATE (contract Food-CT-2006-036224), the US National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (contractNO-ES75558), and the US NIH/National Institute of Neurological Disorders and Stroke (grant 1 UO1 NS 047537-01). M.P. holds a Juan de la Cierva postdoctoral fellowship awarded from the Spanish Ministry of Science and Innovation (JCI-2011-09479) while preparing the pooled data and conducting the initial statistical analyses for the current study and has received funding from the European Research Council (ERC) under the European Union s Horizon 2020 research and innovation programme (grant agreement No 758151) for CHIPS. B.N.H. has received funding from the Instituto de Salud Carlos III (ISCIII) and the European Union NextGenerationEU/PRTR (Grant IHMC22/00017).
Publisher Copyright:
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.